Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1607 + Trastuzumab in HER2+ Advanced Solid Tumors
NCT05555251Phase 2Terminated
- Sponsor
- BioInvent International
- Start
- Jul 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of BI-1607 in breast cancer, gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by BioInvent International. Started Jul 2022; status: terminated.
02
Drugs
BI-1607
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05555251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555251.